In the first phase 2 study of metastatic AR-positive TNBC breast cancer patients, bicalutamide, an AR antagonist, showed a six-month clinical benefit rate of 19% [95% CI, 7–39%] and a median PFS of 12 weeks (95% CI, 11–22 weeks) [238]. This evidence concerns the gene AR and breast cancer.